ArticleFrontiers in oncology2024

Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation.

Chunxia He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.